Invitation to Roche’s Virtual ADA Investor Event
2026-05-07
 We are pleased to invite investors and analysts to participate in our virtual event on Monday, 8 June 2026, to highlight the new data from the Phase II 103 study of enicepatide in obesity, as well as from the Phase II ZUPREME-1 study of petrelintide in obesity, which will be presented at the American Diabetes Association’s (ADA) Scientific Sessions from 05-08 June 2026. 17:00-18:30 CEST / 16:00-17:30 BST 8:00-9:30 PDT / 11:00-12:30 EDT Agenda Introduction Bruno Eschli, Head of Investor Relations Roche obesity strategy Morten Lammert, Global Therapeutic Area Head Cardiovascular, Renal & Metabolism Obesity pipeline overview Manu Chakravarthy, SVP, Global Head of Product Development Cardiovascular, Renal & Metabolism Enicepatide Ph II (103) results in obesity Ildiko Lingvay, MD, MPH, MSCS; Tenured Professor of Medicine in Endocrinology; External consultant to Roche and Genentech Petrelintide Ph II (ZUPREME-1) results in obesity Louis J. Aronne, MD; Past-President of the Obesity Society, Founder and Chair Emeritus of the American Board of Obesity Medicine and Endowed Professor of Metabolic Research; External consultant to Roche and Genentech Q&A The slides will be available for download at 16:00 CEST on the day of the event. > click here Access to virtual event (pre-registration required) Please pre-register for our webinar here*. Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com. A replay of the webcast will be available via > ir.roche.com *privacy notice Best regards, |
| Bruno Eschli Head of Investor Relations | Jan-Philipp Schwarzhans Investor Relations Officer |
| Roche Investor Relations | |
| Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com | Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com |
| Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com | |
| Investor Relations North America | |
| Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com |
Investors
Investor updates
stay updated
get the latest news and updates to your inbox.